Article Details
Retrieved on: 2022-10-11 23:51:59
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Morgan Stanley initiated coverage on CRISPR Therapeutics in a report on Tuesday. They set an "underweight" rating on the stock.
Article found on: www.marketbeat.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here